DMD#62141
Introduction UDP-glucuronosyltransferases (UGTs) are a family of phase II enzymes that catalyze the transfer of glucuronic acid from the cofactor UDP-glucuronic acid (UDPGA) to a large number of endogenous and exogenous compounds, including pharmaceutical drugs (Ritter, 2000) . In humans, there are 19 functional UGT enzymes that are classified into the following three subfamilies: UGT1A, UGT2A, and UGT2B, based on amino acid sequence identity (Mackenzie et al., 2005) . In humans, most of the UGT1 and UGT2 enzymes, including DMD#62141 P450s, which account for the metabolism of 70% of pharmaceutical drugs, has been achieved over the past two decades (Obach et al., 2006) . In contrast, UGT enzymes have attracted relatively less attention for their DDI potential, mostly likely because UGTs account for the metabolism of only 15% of pharmaceutical drugs (Williams et al., 2004) . Despite the lower contribution of UGTs to the clearance of drugs, drug interactions via inhibition of glucuronidation have been clinically observed as follows: (1) atazanavir induces hyperbilirubinemia in carriers of UGT1A1*28 allele (Zhang et al., 2005) ; (2) valproic acid dose-dependently increases the area under the curve of lamotrigine up to 2.5-fold and also inhibits zidovudine and lorazepam glucuronidation (Morris et al., 2000; Kiang et al., 2005) ; and (3) fluconazole significantly alters the pharmacokinetics of zidovudine in HIV patients (Sahai et al., 1994) . However, the majority of these studies have focused on hepatic UGTs and the possible contribution of intestinal UGTs to drug interactions has not been considered.
In this study, we sought to identify inhibitors for either UGT1A8 or UGT1A10 to evaluate potential DDIs caused by the inhibition of intestinal UGTs. We assessed the inhibitory effects of 578 compounds, including drugs, dietary components, environmental xenobiotics, and endobiotics, on raloxifene glucuronidation using recombinant UGT1A8 and UGT1A10. We found that zafirlukast is a potent inhibitor of both UGT1A8 and UGT1A10, although it is also a general UGT inhibitor. We further compared the inhibition properties of zafirlukast against glucuronidation in the liver and the small intestine using UGT substrates, including SN-38, furosemide, S-naproxen, etodolac, and diclofenac, and evaluated potential DDIs. DMD#62141 compounds were dissolved in DMSO and the final DMSO concentration in the incubation mixture was 2%. The reaction mixture was incubated at 37°C for 10 min and the reaction was terminated by the addition of 50 μ l of cold acetonitrile and 20 µL of 0.1 µg/ml haloperidol as an internal standard. After removal of the protein by centrifugation at 12,000 g for 5 min, a 20-μl portion of the sample was subjected to LC-MS/MS.
The LC equipment was comprised of an HP1100 system including a binary pump, an automatic sampler, and a column oven (Agilent Technologies, Santa Clara, CA), which was equipped with a ZORBAX SB-C18 column (2.1 × 50 mm, 3.5 µm; Agilent Technologies). The column temperature was set at 25°C and the flow rate was 200 µl/min. The mobile phase was 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). The conditions for elution were as follows: (1) 5% of B (0-0.5 minutes), (2) 5-50% of B (0.5-7 minutes), (3) 50-100% of B (7-8 minutes), (4) 100% of B (8-13 minutes), and (5) 5% of B (13-18 minutes).
The LC was connected to a PE Sciex API2000 tandem mass spectrometer (AB Sciex, Framingham, MA) operated in the positive electrospray ionization mode. The turbo gas was maintained at 550°C. Nitrogen was used as the nebulizing, turbo, and curtain gases at 60, 85, and 30 psi, respectively. Parent and/or fragment ions were filtered in the first quadrupole and dissociated in the collision cell using nitrogen as the collision gas. The mass/charge (m/z) ion transitions were recorded in the multiple reaction monitoring mode with m/z of 650.1 and 474.2 for raloxifene 4'-and 6-glucuronides and an m/z of 376.1 and 132.0 for haloperidol. The analytical data were processed using the Analyst software (version 1.5; Applied Biosystems, Foster City, CA). All of the data were single determination. Quantification of raloxifene 4'-and 6-glucuronides was performed by comparing the peak-height ratios of the glucuronides to haloperidol (as an internal standard) to those of authentic standards. Residual activities were determined as a percentage of the activity in the control sample. This article has not been copyedited and formatted. The final version may differ from this version. MU glucuronidation by recombinant UGTs (UGT1A1, UGT1A3, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) was examined as described previously (Fujiwara et al., 2007) with slight modifications. Briefly, a typical incubation mixture (100 μ l of total volume) contained 50 mM Tris-HCl (pH 7.4), 10 mM MgCl 2 , 2.5 mM UDPGA, 25 μ g/ml alamethicin, 0.1 mg/ml UGT Supersomes, 0.5-50 µM zafirlukast, and 4-MU. 4-MU concentrations for each UGT isoform were set at values similar to the reported K m or S 50 values shown in Table 1 (Uchaipichat et al., 2004; Fujiwara et al., 2009) . K m is the Michaelis constant in the Michaelis-Menten equation and substrate inhibition model (Houston and Kenworthy, 2000) and S 50 is the substrate concentration that gives half of the maximum enzyme activity (V max ) in the Hill equation (Cornish-Bowden, 1995) . The reaction mixture was incubated at 37°C for 10 min and then terminated by the addition of 100 μ l cold methanol. After removal of the protein by centrifugation at 12,000 g for 5 min, a 50-μl portion of the sample was subjected to HPLC. The formation of 4-MU glucuronide was determined using an L-7100 pump (Hitachi, Tokyo, Japan), an L-7485 FL detector (Hitachi), an L-7200 autosampler (Hitachi), a D-2500 integrator (Hitachi), and a CAPCELL PAK column (4.6 × 150 mm, 5 μ m; Shiseido, Tokyo, Japan). The mobile phase was 30% methanol containing 20 mM potassium dihydrogen phosphate, the flow rate was 1.0 ml/min, and the column temperature was 35°C. Detection was accomplished with a fluorescence detector at 315-nm for excitation and 365-nm for emission.
Quantification of 4-MU glucuronide was performed by comparing the peak-heights to those of the authentic standards.
Diclofenac glucuronidation by recombinant UGTs (UGT1A3, UGT1A9, UGT2B7, and UGT2B17), HLM, and HIM was examined according to a method reported previously Furosemide glucuronidation in HLM and HIM was examined using a method similar to the method used for diclofenac glucuronidation described above. The furosemide concentration was set at a value similar to the reported K m value shown in Table 2 (500 μ M furosemide) (Kutsuno et al., 2013) . The mobile phases were 30% acetonitrile containing 15 mM sodium dihydrogen phosphate. Detection was accomplished with a fluorescence detector at 345-nm for excitation and 450-nm for emission. Quantification of furosemide glucuronide was performed by comparing the peak-heights to those of the authentic standards.
Etodolac glucuronidation in HLM and HIM was examined using a method similar to the method used for diclofenac glucuronidation described above. The etodolac concentration was set at a value similar to the reported K m value shown in Detection was accomplished with a fluorescence detector at 276-nm for excitation and 667-nm for emission. Quantification of etodolac glucuronide was performed as described previously (Kutsuno et al., 2014) .
S-Naproxen glucuronidation in HLM and HIM was examined using a method similar to the method used for diclofenac glucuronidation described above. The S-naproxen concentration was set at a value similar to the reported K m value shown in Table 2 After removal of the proteins by centrifugation at 12,000 g for 5 min, a 20-µl portion of the sample was subjected to HPLC. The formation of SN-38 glucuronide was determined using the same HPLC system used for measuring 4-MU glucuronide with a Mightysil RP-18 GP column detector at 370-nm for excitation and 425-nm for emission. Quantification of SN-38 glucuronide was performed by comparing the peak-heights to those of the authentic standards.
Inhibition kinetics analysis.
The drug concentrations producing a 50% decrease in metabolite formation rate (IC 50 ) for 4-MU, diclofenac, furosemide, etodolac, and S-naproxen glucuronidation were determined from a plot of the logarithm of the inhibitor concentration versus the percentage of the enzyme activity relative to the control by non-linear regression analysis according to the Hill equation with GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA). When the assays are performed at a substrate concentration equivalent to the K m value, inhibition constant (K i ) values are calculated using the following equations: (1) K i = 1/2 × IC 50 for competitive inhibition and (2) K i = IC 50 for noncompetitive inhibition (Cheng and Prusoff, 1973) . Using a competitive inhibition model is considered to be a conservative approach to minimize false-negative predictions because the lowest possible estimate of the K i is obtained.
Accordingly, the present study adopted the former equation.
K i values for the SN-38 glucuronidation were determined by using various concentrations of SN-38 or UDPGA in the presence or absence of zafirlukast as described above. The type of inhibition was determined from a Dixon-plot analysis of the data. K i values were calculated by nonlinear regression analysis using the equation for noncompetitive inhibition (eq. 1) with GraphPad Prism 6.
where V is the velocity of the reaction; and S and I are the substrate and inhibitor concentrations, respectively. This article has not been copyedited and formatted. The final version may differ from this version. The degree of inhibition of the human hepatic UGTs was estimated by calculating the R value (eq. 2) (Bjornsson et al., 2003) , which represents the ratio of intrinsic clearance of a drug in the presence of the inhibitor to that in its absence:
where f u represents the plasma unbound fraction of the inhibitor and I in, max represents the estimated maximum inhibitor concentration at the liver inlet. For the estimation of the R value, I in, max was calculated using eq. 3 (Ito et al., 1998) :
where I max represents the reported value for the maximum plasma concentration in the systemic circulation in the clinical situation; F a represents the absorbed inhibitor fraction; k a represents the absorption rate constant in the intestine; and Q h represents the human hepatic blood flow rate (1610 mL/min). To estimate the maximum I in, max value, F a was set at 1; k a was set at 0.1 min -1 (maximum gastric emptying time [10 min]); and the blood-to-plasma concentration ratio was assumed to be 1.
The degree of inhibition of human intestinal UGTs was estimated by calculating the R value (eq. 4):
I gut = Dose / 250 mL ---Eq. 5
where I gut represents the estimated inhibitor concentration in the small intestine (Zhang et al., 2008 ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Screening of 578 compounds for the inhibition of raloxifene 4'-and 6-glucuronidation by UGT1A8 and UGT1A10.
To find specific inhibitors of either UGT1A8 or UGT1A10, we screened 578 compounds including drugs, dietary components, environmental xenobiotics, and endobiotics for their inhibition of raloxifene 4'-and 6-glucuronidation using recombinant UGT1A8 and UGT1A10
(Supplementary Table 1 ). The control activities of UGT1A8 were 1304 and 445 pmol/min/mg at 10 µM raloxifene for 4'-and 6-glucuronidation, respectively. For UGT1A10, the control activity for 4'-glucuronidation was 443 pmol/min/mg, while the 6-glucuronidation was negligible, in agreement with a previous report (Kemp et al., 2002 preferentially to UGT1A10 and another nine compounds inhibited UGT1A10 preferentially to UGT1A8. Eleven compounds strongly inhibited both UGT1A8 and UGT1A10 activities, and zafirlukast showed the most complete inhibition. Because the inhibition potencies of these compounds were similar between UGT1A8 and UGT1A10, these 29 inhibitors were further investigated for the inhibition of UGT1A1. Most of compounds were found to inhibit UGT1A1 activity (Supplementary Table 2 ), suggesting that these compounds might be non-specific UGT inhibitors. Although we could not find a specific inhibitor for either UGT1A8 or UGT1A10, we subsequently examined the inhibitory potential of zafirlukast on various UGT isoforms.
Inhibitory effects of zafirlukast on 4-MU and diclofenac glucuronidation in recombinant
UGT expression systems.
Next, we characterized the inhibitory effects of zafirlukast on various UGT enzymes using 4-MU as a substrate, which is glucuronidated by almost all of the UGT1A and UGT2B isoforms. zafirlukast potently inhibited the enzyme activities of UGT1A1 (IC 50 values of 0.7 ± 1.1 µM), UGT1A3 (6.3 ± 1.0 µM), UGT1A6 (2.0 ± 1.0 µM), UGT1A8 (1.0 ± 1.1 µM), UGT1A9 (0.6 ± 1.1 µM), and UGT1A10 (3.0 ± 1.0 µM), and moderately inhibited the enzyme activities of UGT2B7 (13.1 ± 1.0 µM) and UGT2B15 (33.4 ± 1.0 µM) (Fig. 1A and Table 1 ). Thus, zafirlukast was found to be a UGT general inhibitor with potent and moderate inhibiting properties to UGT1A and UGT2B isoforms, respectively.
To test whether the inhibitory effect of zafirlukast is substrate-dependent, the inhibitory effects of zafirlukast on diclofenac glucuronidation by recombinant UGT1A3, UGT1A9, UGT2B7, and UGT2B17, the responsible isoforms, was determined (Kuehl et al., 2005) .
Zafirlukast inhibited the activity of UGT2B7 with an IC 50 value of 40.2 ± 1.1 µM (Fig. 1B) and slightly inhibited the activities of UGT1A9 and UGT2B17 with IC 50 values over 50 µM. In contrast, zafirlukast did not inhibit the activity of UGT1A3. Taken together, it was demonstrated that the inhibitory effects of zafirlukast on UGT activities were both substrateand UGT isoform-dependent.
Inhibitory effects of zafirlukast on furosemide, etodolac, S-naproxen, diclofenac, and SN-38 glucuronidation.
To evaluate possible clinical DDIs of glucuronidation inhibition by zafirlukast, we investigated the inhibitory effects of zafirlukast on glucuronidation of drugs including furosemide, etodolac, S-naproxen, and diclofenac in HLM and HIM (Fig. 2) . Furosemide glucuronidation, which is mainly catalyzed by UGT1A1, in HLM and HIM was greatly inhibited by zafirlukast with IC 50 values of 4.9 ± 1.1 and 2.9 ± 1.1 µM, respectively ( Fig. 2A and Table 2 ). Etodolac glucuronidation, which is mainly catalyzed by UGT1A9, in HLM was potently inhibited by zafirlukast with an IC 50 value of 8.7 ± 1.3 µM (Fig. 2B and Table 2 ).
Because etodolac and S-naproxen glucuronidation in HIM were marginal, inhibition analyses
This article has not been copyedited and formatted. The final version may differ from this version. were not conducted. S-naproxen glucuronidation, which is mainly catalyzed by UGT2B7, in HLM was moderately inhibited by zafirlukast with an IC 50 value of 23.2 ± 1.1 (Fig. 2C and Table 2 ). Diclofenac glucuronidation, which is mainly catalyzed by UGT1A9 and UGT2B7, in HLM and HIM were moderately inhibited by zafirlukast with IC 50 values of 26.5 ± 1.1 and 16.1 ± 1.2 µM, respectively ( Fig. 2D and Table 2 ).
Inhibitory effects of zafirlukast were further characterized using glucuronidation of SN-38
(an active metabolite of irinotecan), which is mainly catalyzed by UGT1A1. When SN-38 concentration was varied, SN-38 glucuronidation in HLM and HIM was greatly inhibited by zafirlukast in a noncompetitive manner with K i values of 1.2 ± 0.1 and 1.9 ± 0.1, respectively ( Fig. 3A and 3B ). When UDPGA concentration was varied, SN-38 glucuronidation in HLM was inhibited by zafirlukast in a noncompetitive manner with K i value of 0.7 ± 0.0 (Fig. 3C ).
Taken together, the inhibitory effects of zafirlukast on glucuronidation are substrate-and UGT isoforms-dependent. A tendency was observed that UGT1A-catalyzing reactions (SN-38 and furosemide glucuronidation) were inhibited by zafirlukast more potently than
UGT2B-catalyzing reactions (S-naproxen and diclofenac glucuronidation).

Prediction of the DDI potential of zafirlukast
We next evaluated the potential zafirlukast DDIs with SN-38, furosemide, etodolac, S-naproxen, or diclofenac via inhibition of glucuronidation in the liver and small intestine by calculating the R value. As described in Materials and Methods section, K i values were calculated based on the equation K i = 1/2 × IC 50 , assuming competitive inhibition (Table 3) except for SN-38 glucuronidation. The I max value of zafirlukast was reported to be 0.957 µM after oral administration of 20 mg zafirlukast to healthy subjects (Karonen et al., 2012 1.5, and 1.4, respectively. When the unbound inhibitor concentration (f u = 0.01) was used, the R value, no interaction was predicted for these drugs (i.e., R value < 1.1) ( A series of inhibition studies revealed the following characteristics of zafirlukast as an inhibitor of UGTs: (1) zafirlukast is a general inhibitor of UGTs; (2) zafirlukast more potently inhibits glucuronidation of UGT1A substrates than UGT2B substrates; (3) despite its potency against glucuronidation, zafirlukast is unable to inhibit the glucuronidation of diclofenac. (4) Glcuruonidation of SN-38 was inhibited by zafirlukast in a noncompetitive manner with respect to both SN-38 and UDPGA. Because zafirlukast is unlikely to be a UGT substrate Based on this, zafirlukast is thought to interact with these five drugs. However, if the unbound inhibitor concentration was used, no interaction was predicted (i.e., R value < 1.1).
Nevertheless, we should note that even at the maximum unbound zafirlukast plasma concentration (0.008 µM), which is considerably lower than its K i values for CYP2C9 and CYP1A2 (3 µM and 18 µM, respectively), the interaction with the CYP2C9 substrate S-warfarin or the CYP1A2 substrate theophylline is clinically significant. Therefore, the interaction is feasible even though the predicted R value is below 1.1.
It is well known that inhibition of intestinal drug-metabolizing enzymes leads to clinical
DDIs ( noted that zafirlukast appeared to be less potent inhibitor for UGT2Bs than for UGT1As.
In conclusion, we found that zafirlukast is a general inhibitor for UGTs. 
